Bupropion/zonisamide
Introduction '''Bupropion/zonisamide''' (former tentative brand name '''Empatic''', '''Excalia''') is an experimental combination of bupropion which was under development for the treatment of obesity. Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor. The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.
See also * Naltrexone/bupropion
References